
ISSN : 2347-2251
Indo-American Journal of
Pharma and Bio Sciences
iajpb.editor@gmail.com
editor@iajpb.com
www.iajpb.com

Indo-Am. J. Pharm & Bio. Sc., 2022 *ISSN 2347-2251 www.iajpb.com*

Indo-American Journal of Pharma and Bio Sciences

Vol. 20, Issuse 4, Oct 2022

ACUTE DISSCEMINATED ENCEPHALOMYELITIS

M. Tandrima, Kotha Venkata Krishna, Sumera sultana , Atavali Vipul Kumar Reddy, , Kavitha, and Pavalika

Article Info

Received: 19-07-2022 Revised:20 -08-2022 Accepted: 22-09-2022

Abstract

Multiple neurological abnormalities and changes in mental state are common symptoms of acute disseminated encephalomyelitis (ADEM), a demyelinating and inflammatory disorder of the central nervous system (CNS). ADEM often develops after a health scare or a vaccine. More than a hundred distinct infectious disorders have been linked to encephalitis. Although many other pathogens, including bacteria, parasites, and fungi, are capable of causing encephalitis, viruses are by far the most frequent. It is also uncommon for the systemic symptoms of ADEM, such as fever, malaise, myalgias, headache, nausea, and vomiting, to manifest sometime after the neurological symptoms have developed. A variety of neurological symptoms, including hemiparesis and paralysis, as well as palsies of several cranial nerves.

Key words:

MS stands for Multiple Sclerosis; CSF for Cerebrospinal Fluid; FLAIR for Fluid Attenuation Inversion Recovery; GCS for Glasgow Coma Scale; CT for Computerized Tomography; HSV for Herpes Simplex; HSE for Herpes Simplex Encephalitis; VZV for Varicella Zoster; EBR for Epstein Barr; HHV for Human Herpes; JEV for Japanese Encephalitis; MVEV for Murry Valley; SL

INTRODUCTION

Multifocal neurological acute disseminated encephalomyelitis (ADEM) is a demyelinating and inflammatory condition of the central nervous system that may cause anomalies and changed mental state (CNS). Most cases of ADEM occur after a medical scare or vaccination. Diseases including leptospirosis, campylobacteriosis, borreliosis, rickettsiosis, rickettsii, rickettsi, mycoplasma pneumonia, and chlamydia pneumonia may all be spread by contaminated water. Are all examples of bacteria that might cause it? 1, 2 Polysymptomatic and multifocal clinical signs of ADEM prevail. Most of these diseases are thought to originate from an infection or other environmental trigger leading to immune system dysregulation in an otherwise healthy host with predisposing genetics. Onset of multiple sclerosis occurs in less than 1% of those younger than 10. No infectious agent is detected most of the time3. Currently, the vaccine against measles, mumps, and rubella is most typically related to post vaccination ADEM. It is crucial to understand why the ADEM incidence associated with live measles immunisation (1 to 2 per million) differs from the ADEM incidence traditionally ascribed to measles virus infection (1 in 1,000). Additionally, females are 2.8 times more likely to be diagnosed with juvenile MS than boys4. Confusion was the primary psychiatric symptom in other case reports of ADEM.

Associate Professor Department of Pharmaceutical Chemistry，UCPS Palamuru University,

DNVP，Smt. Sarojini Ramulamma college Of Pharmacy DNVP DNVP

Dhanvanthri College of pharmaceutical sciences Mahabubnagar, Telangana state-509001

Dissociative disorder, 5psychosis,6-7, and infrequently, 7-8.The clinical history of the patient, imaging methods, such as brain CT or MRI, and identification of the distinctive structural lesions are used to make the diagnosis of ADEM. Patients with unusual lesion locations that don't include white matter, on the other hand, might be harder to diagnose and require longer-term care. For the treatment of ADEM, several immunosuppressive drugs have been employed. Although oral prednisolone and dexamethasone have been tried in the past, it is impossible to say whether they are useful[9]. In addition, there aren't any guidelines for these drugs' dosages or other forms of treatment dependent on how serious the condition is. There are anecdotal reports of people with acute fulminant ADEM making a satisfactory recovery after receiving high dose intravenous methylprednisolone, although not all of them do. 10.

Throughout the course of 4 years, we saw 4 sporadic cases with fulminantADEM. In this study, we describe our experiences giving intravenous immunoglobulin (IVIg) in these cases. Based on the temporal proximity of an infection or vaccination to clinical symptoms (such fever, altered state of consciousness, numerous neurological deficits, and even seizures), diffuse white matter lesions on brain imaging, and other factors, the provisional diagnosis of ADEM is made. 11, 12

Long-term therapy is normally not required because ADEM is usually a monophasic illness. High-dose corticosteroids, such as intravenous methylprednisolone, are advised during the initial phase of ADEM 13-16, 17-20, followed by an oral taper. Level IV evidence is, however, limited to this therapy approach because comprehensive therapeutic investigations are not yet available. Numerous case studies have demonstrated that administering intravenous immunoglobulin G (IVIG) is beneficial (class IV evidence). It has been proven that severe demyelinating CNS disease can be successfully treated with plasmapheresis/plasma exchange (PLEX). The two randomised, double-blind clinical trials21, 22 did, however, only involve a small number of ADEM patients. PLEX is often thought of as a rescue therapy for ADEM patients who have a fulminant illness course and a poor response to high-dose corticosteroids. 23 Magnetic resonance imaging (MRI) is a very efficient method for the diagnosis of ADEM. Contrast enhancement is typically present in multifocal lesions of the white matter and basal ganglia.

The posterior fossa and the spine may also be impacted. Even though the lesions are highly suggestive, it's important to remember that other, less common illnesses might exhibit patterns that are similar. Patients with ADEM are referred to by a number of names that correspond to the disease's more obvious symptoms in the literature: The condition was identified as "post infectious or postvaccinal encephalomyelitis, post infectious multifocal encephalitis" after the precipitating events were taken into consideration. Terms used to emphasise the histopathology features and spread of lesions include diffuse vascular myelopathy, perivenous encephalitis, and acute perivascular myelin. "Acute demyelinating encephalomyelitis," "hyper edges encephalomyelitis," "postvaccinal perivenous encephalitis," and "after encephalitis demyelination," 24-35ADE all refer to the likely immunological pathogenetic process. The active phase of mis may last up to three months in most cases.

When new ADEM episodes occur 93 months after the commencement of the illness or 91 months after the conclusion of steroid therapy, this is known as recurrent ADEM (recurrence of early symptoms without involvement of other clinical areas) or multiphasic ADEM.

CASE REPORT

A 50-year-old guy began experiencing fever and headaches on July 28, 2010. He was taken to the emergency room on July 30 after becoming agitated and unresponsive to questions. There was no prior history of substance abuse or contact with dangerous substances. He stayed put in the downtown area for the past few months, never leaving. His Glasgow Coma Scale during testing was (GCS). His body temperature was 38 degrees Celsius, and his neck was flexible. No extrapyramidal symptoms or regional neurological abnormalities were found during a neurological assessment.



Figure 1 Recovery from axial fluid attenuation inversion On August 2, 2010, an MRI taken during the acute stage of Japanese encephalitis reveals bilateral hyperactive intensity lesions at the thalamus (arrows), but no subcortical hyperactive intensity lesions.B).



Figure.2 .Recovery from axial fluid attenuation inversion On October 18, 2010, an MRI taken during the acute stage of ADEM revealed new diffuse white matter lesions on the bilateral juxtacortical (arrows) and periventricular (arrowhead) regions, but the previous thalamic hyper intense lesions had vanished.

The findings of the urgent cranial CT showed nothing unusual in the brain. Despite an abnormally high serum CRP level of 6.53 mg/dL (normal: 0.33 mg/dL), the white blood cell (WBC) count in the peripheral blood was within the usual range. Electrolytes, liver, and kidney functions, as well as all other tests, were all within normal levels. The cerebrospinal fluid showed an increase in protein (81.1 mg/dL) and pleocytosis (46/L) on August 1. (CSF). Acyclovir was given intravenously after he was hospitalised on the suspicion that he had viral encephalitis. On August 2, he stopped having GCS.

On fluid attenuation inversion recovery (FLAIR) sequence (Fig. 1) and T2-weighted images obtained during brain MRI, the thalamus displayed hyper intense change. On MR venography, the cerebral venous system showed no abnormalities. Serum anti-JEV IgM positive was confirmed by further biological tests. Other studies on cancer and autoimmune disorders came up with typical results. Acyclovir was discontinued after the diagnosis of acute Japanese encephalitis. His consciousness gradually grew with diligent, conservative care. He was sent to the treatment facility on September 3 and released on September 17. Except for a mild incidence of discharge irritation, he was conscious and able to stand by himself.

But beginning on October 8 (73 days following the commencement of Japanese encephalitis symptoms, 38 days following his transfer to the rehabilitation centre, and 21 days following his prior discharge, respectively), he started to exhibit escalating dementia and delusions with violent behaviour. He was readmitted on October 15. He allegedly refused to drink the water because he believed it to be oil, according to his wife. He was admitted with a fever of 38°C. Small amounts of exocytosis (14/L) and slightly elevated protein (72.9 mg/dL) were seen in a separate CSF analysis. Viral serological testing revealed a drop in anti-JEV IgM antibody titer and an increase in anti-JEV IgG antibody titer, indicating a stage of recovery from past Japanese encephalitis. On October 18, a brain MRI showed that new multifocal hyper intense lesions of white matter were seen on FLAIR and T2-weighted images, although previously existent thalamic hyper intense lesions had disappeared (Fig. 2). When acute disseminated encephalomyelitis was suspected, a high-dose course of methylprednisolone (1g/day for 5 days) was initiated. His level of consciousness steadily increased after receiving high-dose intravenous steroids, followed by oral methylprednisolone. The multifocal hyper intense lesions on an additional MRI taken on November 23 were smaller compared to the prior film. He was freed on November 27 with small-minded illusions and a negative outlook. After that, his general health started to progressively improve, and six months later he was able to go back to work. A further MRI on June 24 showed no new T2 hyper intensity lesions.

EPIDEMIOLOGY

The true incidence of ADEM is unclear. ADEM originally arose with common childhood diseases including measles, smallpox, and chickenpox, and was linked to serious neurological complications.

ADEM was substantially milder after varicella and rubella infections than after measles infection. ADEM was discovered when researchers found that measles had a fatality rate of up to 25% and a survival rate of 25%-40% with long-term neurological consequences. 45–47 Mycoplasma is the most common bacterial infection linked to the appearance of ADEM. Further illnesses that may be acquired by viruses and bacteria.

The ADEM vaccine is a popular alternative to the traditional (post immunization encephalomyelitis). Clinically, this variant is comparable to the post infectious variant, with the exception that it more usually affects the peripheral nervous system. To create the rabies vaccine, scientists grew the virus in rabbit brains, with the caveat that as many as one in 400 shots might cause neurological issues. Approximately one in 600 to one in 1575 people receiving Simple-type rabies vaccines had neuroparalytic symptoms. Present-day issues include mortality and morbidity. The majority of cases of ADEM in developed countries are attributable to viral infections of the upper respiratory tract, but despite significant advances in infectious illness prevention, the underlying aetiology is still unclear.

Recent research by Murthy et al. found that, despite extensive attempts to detect microbial infections in 18 patients, Epstein-Barr virus was identified as the definite microbiological aetiology of ADEM in just one. One of the other two rotavirus patients was suspected to have an infection related to ADEM. In the absence of a viral cause, the precipitating factors are either rare or intractable by conventional laboratory techniques. 48 Due to poor implementation, immunisation programmes in developing and poor nations are ineffective.

Measles and other viral infections are still widespread and a major cause of post-infectious demyelinating disorders, as reported by several programmes. ADEM is more common in underdeveloped nations than is often believed. 49 One study found that just one in every one thousand measles cases resulted in ADEM. ADEM occurred in just 1 out of every 10,000 people who had recovered from a varicella infection. A one case of ADEM developed after a rubella infection every 500 times.

CAUSES

More than a hundred distinct infectious disorders have been linked to encephalitis. 37 Although many other pathogens, including bacteria, parasites, and fungi, are capable of causing encephalitis, viruses are by far the most frequent. Infections that present clinically as encephalitis are rather rare. Reports of an autosomal recessive immunological deficiency in certain children with herpes simplex virus (HSV) encephalitis suggest that host immunogenetic susceptibilities may be significant (HSE). 38 The level of proof for the causal role of an infectious illness varies. Certain viruses, such as flaviviruses and HSV, fall under this category, whereas others, such as Mycoplasma pneumonia and rotavirus, do not. It's possible that a lot of the hypothesised explanations were uncovered by complete accident. Because of this, modern prospective epidemiological investigation has classified aetiologies as confirmed, probable, or plausible, but prior studies did not make such a careful distinction.

The range of infectious etiologist depends on many parameters, but age, geography, immunisation history, and immune condition are particularly crucial ones. Infectious encephalitis is most often caused by enter virus, varicella zoster virus (VZV), and herpes simplex virus (HSV) in children across the world. Outside of the United States, HSV-1 is the most prevalent cause of HSE; it mostly affects new-borns in Australia. 39, 40, which demonstrates the evolving nature of the genital herpes outbreak. 41, 42 In contrast to adults, older children are disproportionately affected by HSE. 43 Initial research in Europe identified VZV as the leading cause of infantile encephalitis. Post-varicella During these probes, cerebellitis was often diagnosed, despite its absence from subsequent studies. The rate of transmission of varicella should decrease as a result of immunisation. Vacuities is pathologically associated with VZV encephalitis, and its pattern is affected by immunological status. 44

CAUSES OF ENCEPHALITIS

INFECTIOUS

Viral

Human Herpes Viruses 1 and 2, Varicella Zoster Virus, Epstein - Barr virus, Cytomegalovirus, and Human Herpes Virus 6 are all types of herpes viruses (HHV6). beginnings of a virus (coxsakie viruses, numbered includingEv71, Poliovirus) Paramyxoviridae, a family of viruses related to the influenza virus (measles, mumps) Flaviviruses, such as the Powassan virus (POSV), Kunjin virus (KV), St. Louis encephalitis virus (SLEV), tick-borne

encephalitis virus (TBEV), and Murray Valley encephalitis virus (MVEV), are the causative agents of encephalitis.

Chikungunya, the Me Tri virus, the viruses that cause Eastern and Western equine encephalitis, and the virus that causes Venezuelan equine encephalitis are all alpha viruses.

Viruses belonging to the genus Bunya, such as Toscana (TOSV) and La Crosse (LACV) from the Californian serogroup. disease carried by ticks in Colorado (CTFV) Diseases spread by bats, including the Australian bat virus (ABLV), rabies, and the European bat virus (EBLV), the Lyssa and Henipa Viruses (Hendra, Nipah) Infectious human immunodeficiency virus (HIV)

BACTERIAL

- *Listeria monocytogenes*
- *Mycoplasma pneumoniae*
- *Borrelia* (Lyme disease)
- *Treponema Pallidum* (Syphilis)
- *Burkholderia pseudomallei*
- *Mycobacterium.*
- *Tuberculosis.*
- *Leptospira* species.
- *Brucella* species.
- *Bartonella* species.

PARASITIC

- *Toxoplasma gondii*
- *Angiostrongylus cantonensis*
- *Amoeba*
- Trypanosomiasis.

OTHER

- *Rickettsia* species.
- *Ehrlichia* species.
- *Coxiella burneti*
- *Ana plasma* species.

CLINICAL SINGS AND SYMPTOMS

ADEM's neurological symptoms are usually followed by the more generalised malaise, myalgias, headache, nausea, and vomiting. These general symptoms might appear anywhere from four to twenty-one days following the first trigger. Clinical signs of ADEM are characterised by the development of a localised or multifocal neurological illness.

The central nervous system dysfunction reaches its height within a few days. Some of the first clinical signs include lethargy to coma on the part of the patient as well as localised and multifocal neurological symptoms such as hemiparesis, cranial nerve palsies, and paraparesis. Meningismus, ataxia, and other movement disorders are also often reported additional findings. Seizures are a possible complication of ADEM, particularly in the acute hemorrhagic form of the disease. Both left and right sides of the body are commonly affected by transverse myelopathy and optic neuritis. 50, 51–52

Recovery can begin in a matter of days; on rare occasions, complete resolution is noticed in a matter of days, but it typically takes weeks or months. 50% of patients fully recover, and mortality rates range between 10% and 30%. The severity and abruptness of the onset of the clinical syndrome are related to a poor prognosis. Following the rabies vaccination, an 18% death rate was observed in the case series. After an average follow-up of 17 months, 68% of the survivors were completely recovered, 32% were partially recovered, and the majority only had minor deficiencies. Three of the participants in this study experienced a neurological defect that relapsed while they were recovering. None of the patients relapsed once they had fully recovered. 53 Compared to diseases brought on by vaccination, the prognosis of ADEM caused by the measles virus may be worse. Nevertheless, death is rare because of the advancement of effective immunisation techniques and the decline of measles.A recent follow-up analysis of 40 adult patients by Schwarz et al. revealed a decline in the prevalence of prior infections. The most frequently impacted groups are children and young adults.54 Clinically, most adult patients present similarly to children, with the exception that sensory impairments are more common than sensory impairments, while headache, fever, and meningismus are much less common. Optic neuritis is a rare complication of adult ADEM. 54

Pathology

Few details are known about the immunopathogenesis of ADEM. ADEM and MS have been linked, however their connection has been hotly contested for quite some time. While edoema is sometimes the most noticeable finding at autopsy, lesions in ADEM are frequently imperceptible to the naked eye, in contrast to MS. 55,56 Lesions in MS always have a sharp-edged plaque, which has never been found in ADEM lesions, which have clearly defined margins57. This is the fundamental and maybe most visible pathological difference between ADEM and MS. One further diagnostic feature of ADEM is the appearance of demyelinating "sleeves" (Figure 4) around venules and associated with massive inflammatory infiltrates dominated by T cells and macrophages 55. Plasma cells and granulocytes are quite rare. Perivascular lesions, on

the other hand, tend to keep their shape and size over the course of the disease, in contrast to MS lesions, which may develop centrifugally owing to macrophage expansion or confluence59 (Figure 6). Because of this, the most crucial pathophysiological feature distinguishing ADEM from MS is the presence or absence of confluent versus perivenous demyelination60.

This prompted Young et al. to examine if the difference between perivenous and confluent demyelination separates ADEM from MS61. Importantly, this study confirmed that the International Pediatric Multiple Sclerosis Group's diagnostic criteria for ADEM may be used to pathological diagnoses, with an 80% sensitivity and 91% specificity. In comparison to the confluent demyelination cohort, the perivenous demyelination group had a higher incidence of encephalopathy, headache, altered mental status, meningismus, cerebrospinal fluid pleocytosis, and multifocal enhancing magnetic resonance imaging lesions. Six people with perivenous demyelination revealed a typical pattern of cortical microglial activation and aggregation without concurrent cortical demyelination. Four of these patients had poor levels of consciousness, and all six had encephalopathy. A single, severely impaired patient in the confluent demyelination group did not show this pattern of cortical illness. The perivenous demyelination that characterises meningoencephalopathy causes its characteristic clinical presentation and progression. ADEM was misdiagnosed in MS patients due to an altered state of consciousness, which is a more powerful clinical marker for pathologically proven ADEM than encephalopathy. ADEM may have a distinct pattern of microglial activation in the cortex that does not include demyelination as a pathological relation to its reduced awareness. Again, this research shows that the clinical criteria used to distinguish between ADEM and MS are insufficient. It also shows how there is a lot of crossover between the symptoms of these two illnesses on a clinical level. This study raises concerns regarding pathophysiological overlap and misinterpretation between ADEM and MS, since some patients have both perivenous and confluent demyelination at the same time.

ADEM is characterised by widespread inflammation and minimal demyelination localised to the region around the perivascular inflammatory infiltrates, in contrast to MS, where demyelination is the predominant disease (Figure 7). The fourth criteria is the consistency in lesion age. Grey and white matter areas above and below the sagittal plane, as well as the basal ganglia, thalami, and brainstem62, are typical sites to detect them. In most people, the corpus callosum operates properly. MRI studies demonstrate four primary kinds of lesion distribution in Weston Hurst disease, including multifocal lesions less than 5 cm, confluent multifocal lesions more than 5 cm, basal ganglia-affecting multifocal lesions, and multifocal hemorrhagic and oedematous lesions. It is also possible for inflammation to manifest in the meninges and subpial space (microglia and lymphocytes, respectively)64. Lymphocytic meningitis is a potentially life-threatening complication of ADEM. Peripheral nervous system involvement, which has a demyelinating pattern and, if present, is one of the most persuasive evidence confirming the diagnosis of ADEM, occurs in 40% of patients with the disease. However, there haven't been nearly enough pathological examinations of the afflicted peripheral nerves.

Most studies of ADEM's pathology have focused on a single phase of the disease's development, but this article presents five cases of recurrent disease with biopsy findings consistent with ADEM66, such as mononuclear perivascular infiltration, demyelination, white matter laxity, and foamy macrophages. Out of a total of 33 children diagnosed with ADEM, 9 had recurrences during the course of a long-term study67. Those with ADEM had a 27% likelihood of relapsing, but only a 6% chance of developing MS. All relapsing patients had a benign course throughout the whole research, despite experiencing several relapses in the first three years of follow-up. Biopsies were obtained from one patient with multiphase ADEM, one with recurrent ADEM, and one with protracted encephalopathy. In every instance, there was a high number of perivascular lymphocytes, perivascular macrophages, and activated microglia. In places where myelin had been lost, the white matter appeared pale after being stained with Luxol quick blue/periodic acid-Schiff. Neurofilament staining showed that axons were rather well maintained despite the fact that myelin was lost and there were sporadic axonal swellings.

Acute hemorrhagic encephalomyelitis (AHE), or Weston Hurst disease, is a severe variant of ADEM. Similar to ADEM, demyelination is localised to the white matter and perivenular inflammation is seen in this disease. Unlike ADEM, which predominantly displays lymphocytic infiltration, AHE presents as a neutrophilic infiltrate with macroscopically focal haemorrhages, as well as pericapillary ball-and-ring and hematoma hemorrhages68. Commonly seen

comorbidities include perivascular necrosis, edoema, and inflammatory meningeal infiltrates (n = 69).



Figure 3. Venules in brain tissue are surrounded with mononuclear inflammatory cells (H&E, magnification 400 xs).



Figure 4.T cells and macrophages make up the majority of the inflammatory infiltration within the perivascular space (immunohistochemistry to CD3, magnification 400 xs).

Figure 5. Perivenular inflammatory infiltrate is multifocal predominantly composed of T lymphocytes and macrophages (immunohistochemistry to CD3, magnification 100 xs).



Figure 6.Only slight demyelination is associated with perivascular inflammation.

Diagnosis of Acute disseminated encephalomyelitis

ADEM is diagnosed based on the radiological and clinical features. The absence of a verified biological indicator is a major problem. It is important to consider the possibility of Acute Disseminated Encephalomyelitis when a child exhibits multiple neurologic abnormalities with encephalopathy (such as confusion, excessive irritability, or altered level of consciousness) between one and two weeks after a viral infection or vaccination.



Figure7.clinical The identification of a demyelinating episode. Multiple sclerosis, neuromyelitis optica, optic neuritis, transverse myelitis, and clinically isolated syndrome are all names for Acute Disseminated Encephalomyelitis (TM).

Lesions in the thalamus and basal ganglia are often seen in patients. T2-weighted images and fluid-attenuated inversion recovery (FLAIR) sequences are the imaging modalities best suited to identifying the MRI abnormalities seen in ADEM. Acute lesions may exhibit contrast enhancement. ADEM lesions tend to be asymmetrical, poorly defined, and bilateral. Periventricular white matter is often symmetrical and unaffected by lesions, whereas deep and subcortical white matter almost always suffer from some kind of damage.

MRI abnormalities of the brainstem and spinal cord are frequently seen in ADEM73 patients. There are varying amounts of lesions, and their sizes range from 5 mm to 5 cm. 74, 71 Large, confluent intramedullary lesions spanning many spinal cord segments are a common finding in the spinal cord. The contrast improvement might be anything from 71 to 73. According to the disease's past, abnormal MRI results may be shown to grow over a very short time.

TYPES OF ACUTE DISSEMINATED ENCEPHALO MYELITIS[150]

MONOPHASIC ADEM

a new clinical occurrence that affects various CNS regions and is assumed to be brought on by demyelination or inflammation; the clinical presentation must be polysymptomatic and involve encephalopathy, which is characterised by one or more of the following:

- There is a change in cognition, such as lethargy or coma; • There is a change in behaviour, such as disorientation or severe agitation. An improvement should occur after an occurrence in the clinical setting.
- On MRI, or both, however there could still be limitations.
- There is no prior history of the patient experiencing a clinical episode that resembles a demyelinating event.
- There are no other possible causes for the incident.
- Any new or changeable symptoms, signs, or MRI abnormalities are considered to be a part of the acute event if they appear within three months of the ADEM episode that triggered them.
- Neuroimaging demonstrates focal or multifocal lesion(s) largely affecting white matter in the absence of radiologic evidence of preceding harmful white matter alterations.
- On brain MRI, significant (> 1 to 2 cm) lesions that are multifocal, hyper-intense, and located in the supratentorial or infratentorial white matter regions are frequently associated with grey matter, notably the basal ganglia and thalamus.
- Brain MR imaging may occasionally reveal 1 to 2 cm-long large single lesions that mostly harm white matter.
- A lesion with variable enhancement in addition to the atypical brain MRI findings, confluent intramedullary lesions might be identified on a spinal cord MRI.

Recurrent ADEM

Three months have passed since the initial ADEM event without any new clinical regions being involved, as determined by the patient's history, physical examination, or neuroimaging, indicating a new episode of ADEM with a return of the prior symptoms and signs.

The occurrence of the event precedes the end of steroid treatment by at least a month. Although a fresh MRI does not reveal any new lesions, the original tumours may have grown. There isn't a more convincing case.



Figure8.A 37-year-old woman with recurrent episodes of optic neuritis and myelitis had longitudinally extensive myelitis that extended into the corticomedullary region on MRI cervical spine T2W images. She tested positive for NMO-IgG.



Figure 9.A 48-year-old female who intermittently improved between episodes of chronic optic neuritis and recurrent acute partial transverse myelitis. Later, she developed severe quadriparesis and lost sight in her right eye. (A) Axial FLAIR images of the brain show discrete demyelinating lesions in the periventricular and subcortical regions; (B, C) T2-W MRI of the spinal cord reveals a linear coalescing cervical spinal cord lesion that extends beyond three vertebral segments. She tested positive for NMO-IgG.

Multiphase ADEM

The history, neurologic exam, and neuroimaging performed following an ADEM are used to confirm a new clinical event that satisfies ADEM criteria and involves new CNS anatomical areas.

Between the initial ADEM incident and the subsequent episode, at least 3 months must elapse. Additionally, one month must pass after the last dose of steroid medication. The second episode needs to present with multiple symptoms, including encephalopathy and other neurologic symptoms or signs that are distinct from the first. The brain MRI must show the full or partial healing of lesions connected to the initial ADEM occurrence while also revealing additional regions of involvement.

DIFFERENTIAL DIAGNOSIS

In cases where ADEM symptoms appear after an exanthem or vaccination, a definitive diagnosis can be made with relative ease. ADEM is aided by its unusual latent period between systemic symptoms and neurological disease, its typical pattern of diffuse and multifocal involvement of the central nervous system and peripheral nervous system, and its distinctive MRI appearance.

Is there a way to accurately identify and distinguish the earliest stages of multiple sclerosis? The main problem with the ADEM diagnosis is.

109–110 After originally diagnosing 40 patients with ADEM, researchers Schwarz et al. found that 35 percent developed clinically proven multiple sclerosis (Poser's criteria) during the course of an average observation time of 38 months. 111

Schwarz et al. look at possible clinical characteristics for discrimination but fail to find any distinctive characteristics that are particular to each condition. The same is true for CSF fluid anomalies, which aren't different enough to tell one patient with ADEM from another with multiple sclerosis.

Multiple sclerosis and ADEM are difficult to identify, according to MRI research. Approximately 50% of ADEM patients showed MRI signs consistent with multiple sclerosis. 111 Adult ADEM patients often exhibit a more serious, all-pervasive central nervous system disturbance, which leads in unconsciousness and multifocal symptoms. Fever, unconsciousness, and meningism are strongly predictive of ADEM even though they are uncommon in multiple sclerosis despite the fact that they are rarely detected.

Hynson et al. have noted that it can be challenging to discern between an initial MS episode and In children, ADEM occurs. The authors state that ADEM is more likely to be diagnosed when there is a viral prodrome, early start of ataxia, a high lesion load on an MRI, involvement of the deep cortical grey matter, and the lack of oligoclonal bands. 112 One MRI scan may no longer be able to differentiate between ADEM and MS. Conducting studies in a sequence, with at least six months between each, may provide better results. The discovery of new lesions is an important diagnostic sign in multiple sclerosis. If a clinical relapse has not happened in a patient with ADEM, then new lesions should not arise. 113 The presence of enhancing and non-enhancing lesions shows that gadolinium-enhanced MRI may be used to differentiate between these two demyelinating disorders.



Figure 10. patient's MRI one week prior to a feverish illness Frontal lobe white matter is extensively demyelinated on T1 (A) and T2 (B) images. This 20-year-old woman was diagnosed with significant pyramidal symptoms, bilateral vision loss, and cerebellar indications.

TREATMENT

DIET AND LIFESTYLE

The occurrence and manifestation of ADEM may be influenced by environmental factors, such as diet and lifestyle, even if there aren't many credible epidemiologic research. vitamin D, Following a first demyelinating episode, recent research has linked low vitamin D levels to an increased chance of developing multiple sclerosis. 118 However, no studies have identified low vitamin D levels in ADEM patients. The highest ADEM incidence rates to date have been found in Fukuoka, Japan (33°-34°N) and San Diego County, California, USA (32°-33°N), although lower rates have been seen in countries with higher latitudes, such as Canada (41°-84°N) and Germany. There are no accessible acratgeographical incidence data for ADEM. (47°–55°N) [119–121, 122, 123].

PHARMACOLOGIC TREATMENT

PREDNISOLONE

METHYL PREDNISOLONE

Standard dosage

Prednisolone at a dosage of 1-2 mg/kg/day used orally for 1-2 weeks, followed by a 2–6 week taper. Methylprednisolone 20–30 mg/kg (up to 1 g) administered intravenously every day for three days.

Contraindications

Live or attenuated live vaccine hypersensitivity; systemic fungal infection; recent or current varicella, vaccinia, measles, or tuberculosis infection; history of brain malaria; peptic ulcer; renal insufficiency; Glaucoma, amebiasis, strongyloidiasis, latent TB infection, recent myocardial infarction, renal impairment, hypokalemia, and risk of gastrointestinal perforation are all factors to take into account (from conditions like diverticulitis, ulcerative colitis, or recent intestinal anastomoses).

Main side effects Serious

angioedema, hyperglycemia, elevated intraocular pressure or glaucoma, cataracts, growth inhibition, infection, cardiac arrest, arrhythmias, congestive heart failure, pulmonary edoema, syncope, thromboembolism, and Kaposi sarcoma. vas Increased intraocular pressure, glucose intolerance, sodium/fluid retention, hypertension, eczema, rash, skin atrophy, weight gain/increased appetite, irritability, hyperhidrosis, hirsutism, menstrual irregularities, nausea, elevated liver enzymes, headache, insomnia, paresthesia, vertigo, and neuropathy are common side effects. The usual dose is 2 g/kg intravenously (IV) over the course of two to five days.

Main side effects

be wary of the black box Osmotic nephrosis, acute renal failure, and renal impairment have all been linked to IVIGs, and there have been fatalities associated with their use. Acute renal failure is more likely to occur in those with a history of renal insufficiency, diabetes, advanced age, volume depletion, infection, elevated protein in the blood (paraproteinemia), or the use of nephrotoxic drugs. This population, in particular, needs IVIG administered at the weakest concentration and slowest infusion rate possible. Pohl and Tenembaum 267 found that a disproportionate number of patients with acute disseminated encephalomyelitis were treated with stabilisers that contained sucrose, despite the fact that several of the licenced IVIG treatments have been linked to reports of renal dysfunction and acute renal failure. Acute transfusion-induced lung injury (ATILI), Stevens-Johnson syndrome (SJS), erythema multiforme (EMF), nephrotoxicity (NT), hyperproteinemia (HP), pseudohyponatremia (PH), hyperviscosity (HV), aseptic meningitis (AM), hemolytic anaemia (HBA), and viral transmission are all potentially fatal complications. Back pain, fatigue, chest tightness, muscle cramps, headaches, injection site responses, nausea, vomiting, rashes, urticaria, fever, chills, rigors, flushing, and unstable blood pressure are the most common adverse effects of upper respiratory infections.

Interventional procedures

Plasmapheresis

Plasmapheresis is a non-selective immunological treatment that separates plasma from the cytokines, complement, and pathogenic antibodies present in corpuscular blood using centrifugation or membrane filtration. Modulation of the humoralimmune system 124 is the fundamental mechanism through which plasmapheresis treatments exert their curative benefits in autoimmune disorders. Class II evidence 125 suggests the treatment may be useful as an escalation therapy for patients with acutefulminant demyelinating central nervous system illnesses such ADEM, MS, NMO, and transverse myelitis who have

not responded to corticosteroids. In a few rare instances of ADEM in both adults and children, plasmapheresis has been described as an effective therapy. 126–131.

Standard procedure

5-7 exchanges with a 1:1 exchange every other day.

Contraindications

Hypersensitivity to agents used in PLEX.

Complications

Moderate to severe anaemia, thrombocytopenia brought on by heparin, symptomatic hypotension, danger of hypocalcemia, immune suppression, potential transfusion reactions or disease transfer, and immunological suppression. Serious bleeding condition: proceed with caution (line insertion may be associated with bleeding). Difficulties with catheters (line infections, line thrombosis, pneumo, and thorax). If human albumin is used instead, the danger of infection is reduced.

Special points

When using plasmapheresis on young children, exercise caution as significant volume shifts could occur, potentially resulting in hemodynamic instability.

SURGERY

Craniectomy

Decompressive craniectomy has been found to reduce intracranial pressure in life-threatening situations, such as stroke or severe head trauma (ICP). Patients with fulminant ADEM had surgical decompression if they exhibited evidence of increasing clinical deterioration owing to increased ICP, were refractory to routine medical therapy, and needed critical care measures (level IV) 132-138. Both children and adults were among the victims. We looked at 268 patients diagnosed with neuroimmune diseases (R Lisak, Section Editor). Unfortunately, there have been no prospective clinical studies evaluating the effectiveness of craniotomy for treating fulminant types of ADEM with increased intracranial pressure (ICP).

Standard procedure

Hemicraniectomy, bilateral frontal craniectomies with duraplasty, subtotal unit-, or posterior fossa craniectomies.

Contraindications

In patients with very low Glasgow ComaScale, there is a tendency toward a high incidence of mortality or persistent vegetative state despite aggressive therapy. The advice to refrain from performing surgery on patients with a GCS of less than 5 is still up for debate.[139]

Complications Major

Permanent neurological impairments, osteomyelitis, subdural hematomas, extradural hematomas, hydrocephalus, and neuropsychological impairment. Small-scale convulsions, CSF leaks, subgaleal fluid accumulation, surgical site infections, and temporary neurological impairments.

PHYSICAL/SPEECH THERAPY AND EXERCISE

Physical therapy

Usage

Gait, balance, and muscle strength improvement. Contraindications There are no limitations. Unique points when a severe ADEM event occurs, patients with motor deficits or coordination issues may require physical therapy.

Speech therapy

Occasionally, transient or persistent language deficits have been linked to speech disorders caused by ADEM, especially in the youngest age group. Patients with ADEM who primarily have cerebellar involvement have also been found to have cerebellar mutism. 141. In one study, half of the children with ADEM had subtentorial demyelinating lesions found on brain MRI scans 142. On follow-up after an ADEM event, neurocognitive and speech disturbances may be significant despite limited physical disability.

Usage

Enhancement of speech fluency, articulation, and both receptive and expressive language.

Contraindications

NO contraindications.

Special points

Patients with persistent speech disorders should be treated with speech and language therapy, which should be viewed as a crucial component of their care. Pohl and Tenembaum 269 discuss how to treat acute disseminated encephalomyelitis.

Exercise

Exercise has not been studied as a treatment for young people with ADEM.

Usage

Patients with transitory motor skill loss may benefit from using this to increase their muscle strength.

Special points

To design an exercise programme that suits the age and needs of each patient, you might need advice from a physiotherapist or personal trainer.

OTHER TREATMENTS

Immunosuppressive drugs

Cyclophosphamide usage has been documented in a small number of adult patients with steroid-resistant forms of ADEM (level IV)143, 144, and 145. There is no information available on the usage of immunosuppressive medications in paediatric ADEM patients. However, one study in children with severe MS unresponsive to first-line treatments provided safety and tolerability evidence for cyclophosphamide. [146, 149].

Cyclophosphamide

Standard dosage

The ideal dosage has not been determined. Demyelinating diseases such as ADEM, MS, andTM have been reported to respond to doses of 500–1000 mg/m2 given as a single dose or as part of an induction regimen on days 1, 2, 4, 6, and 8. [147, 146, 148].

Contraindications

hypersensitivity to drugs BCG (live intravesical), live vaccinia/smallpox vaccine, nasal influenza vaccines, immunosuppression, severe leucopenia/bone marrow depression, pregnancy, and breastfeeding. Notification: recent radiation therapy, recent use of cytotoxic drugs, recent hepatic or renal impairment, leucopenia, thrombocytopenia, and adrenalectomy

Main side effects Serious

Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, secondary malignancy, infertility (permanent or temporary), hemorrhagic cystitis, urinary bladder fibrosis, congestive heart failure, hemorrhagic myocarditis, immunosuppression, infection, anaemia, leucopenia, thrombocytopenia, and interstitial pulmonary fibrosis are just some of the symptoms Alopecia, sterility, amenorrhea, nausea, vomiting, anorexia, diarrhoea, stomatitis, hemorrhagic cystitis, rash, and headache are the most often reported side events after an infusion.

Special points

Both male and female postpubertal patients are advised to use contraception while undergoing treatment.

Emerging therapies

Patients with acute demyelinating illnesses like ADEM have not been observed to use new treatments for MS.

CONCLUSION

Despite the widespread awareness of ADEM syndrome, there is still no universally accepted set of diagnostic criteria. To our knowledge, no studies have ever attempted to compare clinical diagnostic criteria to a pathological gold standard. ADEM is often characterised by increased white-matter lesions on cranial MRI and an inflammatory CSF profile, as well as an abrupt, fulminant, multifocal central nervous system presentation with meningeal symptoms and signs after a clearly defined viral or inflammatory trigger. In certain cases when ADEM was first suspected, a later diagnosis of multiple sclerosis, neuromyelitis optica, or another illness may provide light on the original diagnosis. Due to the lack of clarity in the nosological classification of central nervous system demyelinating diseases, physicians must use all available diagnostic tools, such as longitudinal observation and biopsies, to arrive at an accurate clinical diagnosis.

ADEM is being rethought, even if there aren't yet agreed-upon clinical diagnostic criteria. Even the strict criteria for ADEM cannot reliably predict a monophasic outcome when patients present with early bouts of an idiopathic inflammatory demyelinating illness. Due to the clinical and neuroimaging features of encephalopathy, including polysymptomatic presentation, large, multifocal MRI lesions involving deep grey matter and cortex, and CSF pleocytosis without OCBs, other mimickers of inflammatory demyelinating disease must be considered in addition to ADEM. Testing for NMO is warranted in patients with myelitis or ON, particularly those who test positive for NMO-IgG.

References

1. Menge T, Hemmer B, Nessler S, et al. Acute DisseminatedEncephalomyelitis an update. Arch Neurol 2005;62:1673-80.
2. Tenembaum S, Chitnis T, Ness J, Hahn JS; International Pediatrics Study Group. Acutedisseminated encephalomyelitis. Neurology 2007;68:S23-36.
3. Gadoth N. Multiple sclerosis in children. Brain Dev 2003;25:229-32.
4. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al.Natural history of multiple sclerosis with childhood onset. N Engl J Me2007;356:2603-13.9. Tei H, Soma Y, Iwata M. Korsakoff's syndromeas the first clinical manifestation of acutedisseminated encephalomyelitis. Behav Neurol1995; 8 : 181–185.
5. Moscovich DG, Singh MB, Eva FJ, et al. Acutedisseminated encephalomyelitis presenting as an acute psychotic state. J Nerv Ment Dis 1995;183:116.
6. Nasr JT, Andriola MR, Coyle PK. ADEM:literature review and case report of acute psychosis presentation. Pediatr Neurol 2000;22 : 8–18.
7. Abay E, Balci K,Ates I. Acute Disseminated Encephalomyelitis Presenting as ConversionDisorder J Neuropsychiatry Clin Neurosci2005; 17 : 259-260.152.
8. Straub J, Chofflon M, Delavelle J. ADEM is believed to be the clinical counterpart of methylprednisolone in ADEM Neurology 1997;49:1145–7.
9. Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ever, in addition to cell mediated delayed hypersensitivity ME, Churchill Jr WH. Neurology 1995;45:824–7.1.
10. Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O,Hartung HP, Kieseier BC Stuve O. Acute disseminated encephalomyelitis: An update. Arch Neurol 2005;62:1673-1680
11. Tenembaum S, Chitnis T, Ness J, Hahn JS. Acutedisseminated encephalomyelitis. Neurology 2007;68:S23-S36.
12. Pohl D. Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions. Curr Opin Neurol. 2008;21(3):366–72.
13. Torisu H, Kira R, Ishizaki Y, Sanefuji M, Yamagishi, Yasumasa S, et al. Clinical study of childhoodacute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis inFukuoka Prefecture, Japan. Brain Dev. 2010;32(6):454–62.
14. Ketelslegers IA, Visser IE, Neuteboom RF, Boon M,Catsman-Berrevoets CE, Hintzen RQ. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. MultScler. 2011;17(4):441–8.
15. Visudtibhan A, Tuntiyathorn L, Vaewpanich J, SukjitP, Khongkatithum C, Thampratankul L, et al. Acutedisseminated encephalomyelitis: a 10-year cohort study in Thai children. Eur J Paediatr Neurol.2010;14(6):513–8.
16. Marchioni E, Tavazzi E, Minoli L, Del BS, Ferrante P,Piccolo G, et al. Acute disseminated encephalomyelitis. Neurol Sci. 2008;29 Suppl 2:S286–8.
17. McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A.Immunomodulatory therapies in neurologic criticalcare. Neurocritical Care. 2010;12(1):132–43.
18. Sonneville R, Klein IF, Wolff M. Update on investigationand management of postinfectious encephalitis. Current Opinion in Neurology. 2010;23(3):300–4.
20. Weiner HL, Dau PC, Khatri BO, Petajan JH,Birnbaum G, McQuillen MP, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of MS. Neurology.1989;39(9):1143–9.
21. Weinshenker BG, O'Brien PC, Petterson TM,Noseworthy JH, Lucchinetti CF, Dodick DW, et al.A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878–86.
22. Shinozaki K, Oda S, Sadahiro T, Nakamura M, Abe R,Nakamura S, et al. A case report of plasmapheresis in the treatment of acute disseminated encephalomyelitis. Her Apher Dial. 2008;12(5):401–5.
23. Marsden JP, Hurst EW. Acute perivascular myelinolysis (‒acute disseminated encephalomyelitis‖) in smallpox. Brain 1932;55:181–193.
24. Davison C, Brock S. Acute demyelinating encephalomyelitis following respiratory disease. Bull Neurol Inst NY 1937;6:504–514.
25. Bogaert L. Post-infectious encephalomyelitis and multiple sclerosis; thesignificance of perivenous encephalomyelitis. J Neuropathology Exp Neurol 1950;9:219–249.
26. Ferraro A, Roizin L. Hyperergic encephalomyelitis's following exanthematic diseases, infectious diseases and vaccination. J NeuropatholExp Neurol 1957;16:423–445.
27. DeVries. Postvaccinal perivenous encephalitis. Amsterdam: Elsevier,1960.
28. Carpenter S, Lampert PW. Postinfectious perivenous encephalitis and acute hemorrhage ice leukoencephalitis. In: Minckler J, ed. Pathology of the nervous system. New York: McGraw-Hill, 1968:2260–2269.
29. Poser ChM. Disseminated vasculomyelinopathy. A review of the clinical and pathologic reactions of the nervous system in hyperergic diseases. Acta Neurol Scand 1969:37 suppl:3344.
30. Pasternak JF, De Vivo DC, Prensky AL. Steroid responsive encephalomyelitis in childhood. Neurology 1980;30:481–486.
31. Lukes SA, Norman D. Computed tomography in ADEM. Ann Neurol 1983;13:567–572.
32. Dunn V, Bale JF, Zimmerman RA, Perdue Z, Bell WE. MRI in children with postinfectious disseminated encephalomyelitis. Magn Reson Imaging 1986;4:25–32.
33. 2Boulloche J, Parain D, Mallet E, Tron P. Postinfectious encephalitis with multifocal white matter lesions. Neuropediatrics 1989;20:173–175.
34. Brinar VV. Non-MS recurrent demyelinating diseases. Clin Neurol Neurosurg2004;106:197–210.
35. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Agenlocher Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001;56:1313–1318.
36. A Possible Case of Acute Disseminated Encephalomyelitis after Japanese EncephalitisWei-Liang Chen1, Ming-Feng Liao2, Han-Lin Chiang3, Shinn-Kuang Lin3,4
37. Granerod J, Crowcroft NS. The epidemiology of acute encephalitis. Neuropsychol. 2007; **17**: 406–28.
38. Takanashi J. Two newly proposed infectious encephalitis/encephalopathy syndromes. Brain Dev. 2009; **31**: 521–8.
39. Jones CA, Isaacs D, McIntyre P, Cunningham A, Garland S. Neonatal herpes simplex virus infection. In: Ridely G, Zurynski Y, Elliott EJ, eds. Australian Paediatric Surveillance Unit Research Report, 2007–8. Sydney: APSU, 2010; 24. ISSN: 1443-3524.
40. Kropp RY, Wong T, Cormier L et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics 2006; **117**: 1955–62.
41. Haddow LJ, Dave B, Mindel A et al. Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003. Sex. Transm. Infect. 2006; **82**: 255–9.
42. Bernstein DI, Bellamy AR, Hook EW 3rd et al. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin. Infect. Dis. 2013; **56**: 344–51.
43. Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin. Pediatr. Infect. Dis. 2005; **16**: 17–23.
44. Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. 2007; **6**: 1015–28.

45. Litvak AM, Sands IJ, Gibel H. Encephalitis complicating measles: report of 56 cases with follow-up studies in 32. Is J Dis Child 1943; 65:265–95.
46. Miller HG, Evans MJ. Prognosis in acute disseminated encephalomyelitis: with a note of neuromyelitis optica. Q J Med1953; 22:247–79.
47. Stuve O, Zamvil SS. Pathogenesis, diagnosis and treatment of acute disseminated encephalomyelitis. Curr Opin Neurology1999;12:395–401
48. Murthy SNK, Faden HS, Cohen ME, et al. Acute disseminated encephalomyelitis in children.Pediatrics2002;110(2)(http://www.pediatrics.org/cgi/content/full/110/2/e21).
49. Murthy JM, Yangala R, Meena AK, et al. Acute disseminated encephalomyelitis: clinical and MRI study from South India. J Neurol Sci1999;165:133–8.
50. Stuve O, Zamvil SS. Pathogenesis, diagnosis and treatment of acute disseminated encephalomyelitis. Curr Opin Neurology1999;12:395–401.
51. Murthy JMK, Yangala R, Meena AK, et al. Clinical, electrophysiological and magnetic resonance imaging study of acute disseminated encephalomyelitis. J Assoc Physicians India1999;47:280–3.
52. Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical andneuroradiologic features of acute disseminated encephalomyelitis inchildren. Neurology2001;56:1308–12.
53. Schwarz S, Mohr A, Knauth M, et al. Acute disseminatedencephalomyelitis: a follow-up study of 40 adult patients.Neurology2001;56:1313–18.
54. Held JR, Adros HL. Neurological disease in man following administration ofsuckling mouse brain antirabies vaccine. Bull WorldHealth Organ1972;46:321–7.
55. Hart M. N., Earle K. M., Haemorrhagic and perivenous encephalitis: a clinical–pathological review of 38 cases, J. Neurol. Neurosurg. Psychiatry, 1975, 38, 585–591
56. Gold R., Linington C., Lassmann H., Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research, Brain, 2006, 129:1953-1971
57. Kadlubowski M., Highes R., The neuritogenecity and encephalogenecity of P2 in in therat, guinea pig and rabbit, J. Neurol. Sci., 1980, 48, 171-178
58. van Bogaert L., Post-infectious encephalomyelitis and multiple sclerosis. The significance of perivenous encephalomyelitis, J. Neuropathol. Exp. Neurol., 1950, 9, 219–249
59. Wegner C., Pathological differences in acute inflammatory demyelinating diseases of the central nervous system, Int. MS J.,2005, 12, 12-19
60. Lassmann H., Acute disseminated encephalomyelitis and multiple sclerosis, Brain, 2010, 133, 317-319
61. Young N. P., Weinshenker B. G., Parisi J. E., Scheithauer B., Giannini C., Roemer S. F. et al., Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis, Brain, 2010, 133, 333-348
62. Garg R.K., Acute disseminated encephalomyelitis, Postgrad. Med. J., 2003, 79, 11-17
63. Rossi A., Imaging of acute disseminated encephalomyelitis, Neuroimaging Clin. N.Am.,2008, 18, 149e61
64. Wingerchuk D. M., Lucchinetti C. F., Comparative immunopathogenesis of ADEM,neuromyelitis optica, and MS , Curr.Opin. Neurol., 2007, 20, 343-350
65. Marchioni E., Ravaglia S., Piccolo G., Furione M., Zardini E., Franciotta D. et al.,Postinfectious inflammatory disorders: subgroups based on prospective follow-up,Neurology, 2005, 65, 1057-1065
66. Cohen O., Steiner-Birmanns B., Biran I., Abramsky O., Honigman S., Steiner I.,
Recurrence of acute disseminated encephalomyelitis at the previously affected brain site,Arch. Neurol., 2001, 58, 797-801
67. Mar S., Lenox J., Benzinger T., Brown S., Noetzel M., Long-term prognosis of pediatric patients with relapsing acute disseminated encephalomyelitis, J. Child Neurol., 2010, 25,681-688
68. Kuperan S., Ostrow P., Landi M. K., Bakshi R., Acute haemorrhagic leukoencephalitis vs. ADEM: FLAIR MRI and neuropathology findings, Neurology, 2003, 60, 721-722
69. Fontoura P., Leucoencefalitis aguda hemorragica de Weston Hurst.Estudio neuropatologico de un caso, Rev. Neurol., 2002, 35, 328–33.
70. Tenembaum S, Chamoles N, Fejerman N. ADEM: a long-term follow-up study of 84 pediatric patients. Neurology 2002;59:1224-31.
71. Tenembaum S, Chitnis T, Ness J, Hahn JS; International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007;68(16 Suppl 2):S23-36
72. Baum PA, Barkovich AJ, Koch TK, Berg BO. Deep gray matter involvement in children with ADEM. AJNR Am J Neuroradiology 1994;15:1275-83.
73. Stonehouse M, Gupte G, Wassmer E, Whitehouse WP. Acute dis• seminated encephalomyelitis: recognition in the hands of general pediatricians. Arch Dis Child 2003;88:122-4.
74. Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. ADEM,multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000;123 Pt 12:2407-22.
75. Litvak AM, Sands IJ, Gibel H. Encephalitis complicating measles: report of 56 cases with follow-up studies in 32. Am J Dis Child 1943;65:265–95.
(http://www.pediatrics.org/cgi/content/full/110/2/e21).
76. Murthy JM, Yangala R, Meena AK, et al. Acute disseminated encephalomyelitis: clinical and MRI study from South India. J Neurol Sci 1999;165:133–8.
77. Scully RE, Mark EJ, McNeely WF, et al. Case records of the Massachusetts General Hospital, case 37–1995. N Engl J Med 1995;333:1485–92.
78. Stefansson K, Hedley-Whyte ET. Case records of the Massachusetts General Hospital, case 8−1996—a 28 years old woman with rapid development of a major personality change and global aphasia. N EnglJ Med 1996;334:715–21.
79. Hollinger P, Sturzenegger M, Mathis J, et al.ADEM in adults: a reappraisal of clinical CSF, EEG and MRI findings. J Neurol 2002;249:320–9.
80. Lukes SA, Norman D. Computed tomography in acute disseminated encephalomyelitis. Ann Neurol 1983;13:567–72.
81. Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001;56:1313–18.
82. Apak RA, Kose G, Anlar B, et al. Acute disseminated encephalomyelitis in childhood: report of 10 cases. J Child Neurol 1999;14:198–201.
83. Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000;123:2407–22.
84. Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001;56:1308–12
85. Caldmeyer KS, Smith RR, Harris TM, et al. MRI in acute disseminated encephalomyelitis. Neuroradiology 1994;36:216–20.
86. Singh S, Alexander M, Korah IP. Acute disseminated encephalomyelitis: MR imaging features. AJR Am J Roentgenol 1999;173:1101–7.
87. O'Riordan JI, Gomez-Anson B, Moseley IF, et al. Long-term MRI follow-up of patients with post-infectious encephalomyelitis: evidence for a monophasic disease. J Neurol Sci 1999;167:132–6.
88. Bizzi A, Ulug AM, Crawford TO, et al. Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis. AJNRAm J Neuroradiol 2001;22:1125–30.
89. Miller HG, Evans MJ. Prognosis in acute disseminated encephalomyelitis: with a note of neuromyelitis optica. Q J Med 1953;22:247–79
90. Gupte G, Stonehouse M, Wassmer E, et al. Acute disseminated encephalomyelitis: a review of 18 cases in childhood. J Paediatr Child Health 2003; 39:336–42.
91. Pavone P, Pettoello-Mantovano M, Le Pira A, et al. ADEM a long-term prospective & meta-analysis. Neuro-Pediatrics 2010;41:246–55
92. Tenembaum S, Chamoles N, Fejerman N. ADEM: long-term follow-up study of pediatric patients. Neurology 2002; 59:1224–31.
93. Mikaeloff Y, Caridade G, Husson B, et al. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol 2007;11:90–5.
94. Visudtibhan A, Tuntiyathorn L, Vaewpanich J, et al. Acute disseminated encephalomyelitis: a 10-year cohort study in Thai children. Eur J Paediatr Neurol 2010;14:513–8.
95. Callen DJ, Shroff MM, Branson HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009;72:968–73.

96. Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neuro-surg Psychiatry 2000;68:157–61
97. Inglese M, Salvi F, Iannucci G, et al. Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. AJNR Am J Neu-roradiol 2002;23:267–72.
98. Balasubramanya KS, Kovoor JM, Jayakumar PN, et al. Diffusion-weighted imaging & proton MR spectros-copy in the characterization of acute disseminated encephalomyelitis. Neuroradiology 2007;49:177–83.
99. Harada M, Hisaoka S, Mori K, et al. Differences in water diffusion and lactate production in two different types of postinfectious encephalopathy. J Magn Reson Imaging 2000;11:559–63.
100. Chen CI, Mar S, Brown S, et al. Neuropathologic correlates for diffusion tensor imaging in postinfectious encephalopathy. Pediatr Neurol 2011;44: 389–93.
101. Bizzi A, Ulug AM, Crawford TO, et al. Quantitative proton MR spectroscopic imaging in ADEM. AJNR Am J Neuroradiology 2001;22:1125–30.
102. Ben Sira L, Miller E, Artzi M, et al. ^{1}H-MRS for the diagnosis of acute disseminated encephalomyelitis: insight into the acute-disease stage. Pediatr Radiol 2010;40:106–13
103. Rovira A, Pericot I, Alonso J, et al. Serial diffusionweighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. AJNR Am J Neuroradiol 2002;23:989–94.
104. Tabata K, Shishido F, Uemura K, et al. Positron emission tomography in acute disseminated encephalomyelitis: a case report. Kaku Igaku 1990;27:261–5 [in Japanese].
105. Broich K, Horwich D, Alavi A. HMPAO-SPECT and MRI in acute disseminated encephalomyelitis. J Nucl Med 1991;32:1897–900.
106. San Pedro EC, Mountz JM, Liu HG, et al. Postinfec-tious Cerebellitis: clinical significance of Tc-99m HMPAO brain SPECT compared with MRI. Clin Nucl Med 1998;23:212–6.
107. Itti E, Huff K, Cornford ME, et al. Postinfectious encephalitis: a coregistered SPECT and magnetic resonance imaging study. Clin Nucl Med 2002;27:129–30.
108. Okamoto M, Ashida KI, Imaizumi M. Hypoperfusion following encephalitis: SPECT with acetazolamide. Eur J Neurol 2001;8:471–4.
109. Hartung HP, Grossman RI. ADEM: distinct disease or part of MS spectrum? Neurology2001; 56:1257–60.
110. Barkhof F, Filippi M, Miller DH, et al. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059–69.
111. Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: a follow-upstudy of 40 adult patients. Neurology 2001; 56:1313–18.
112. Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56:1308–12.
113. Stuve O, Zamvil SS. Pathogenesis, diagnosis and treatment of acute disseminatedencephalomyelitis. Curr Opin Neurology 1999;12:395–401.
114. Hung KL, Liao HT, Tsai ML. Post-infectious encephalomyelitis: etiologic and diagnostic trends. J Child Neurol 2000; 15:666–70.
115. Dey KB, Trikha I, Banerjee M, et al. Acute disseminated encephalomyelitis—anothercause of post malaria cerebeller ataxia. J Assoc Physicians India 2001; 49:756–8.
116. Mohsen AH, Mckendrick MW, Schmid ML, et al. Postmalaria neurological syndrome: a case of disseminated encephalomyelitis. J Neurol Neurosurg Psychiatry 2000; 68:388–90.
117. Hollinger P, Sturzenegger M, Mathis J, et al. ADEM in adults: a reappraisal of clinical CSF, EEG and MRI findings. J Neurol 2002; 249:320–9
118. Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011; 10(5):436–45.
119. Pohl D, Hennemuth I, von Kries R, Hanefeld F. Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr. 2007;166(5):405–12.
120. Leake JA, Albani S, Kao AS, Senac MO, Billman GF, Nespeca MP, et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J. 2004; 23 (8):756–64.
121. Torisu H,–9 Kira R, Ishizaki Y, Sanefuji M, Yamaguchi Y, Yasumoto S, et al. Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture, Japan. Brain Dev. 2010; 32 (6):454–62.
122. Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009 Jan 20; 72(3):232.
123. Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011; 77(12):1143–8.
124. Schroder A, Linker RA, Gold R. Plasmapheresis for neuroinflammatory disorders. Clinical and Experimental Neuroimmunology. 2010; 1(3):95– 102
125. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.Neurology.2011; 76(3):294–300.
126. RamachandranNair R, Rafeequ M, Girija AS. Plasmapheresis in childhood acute disseminated Encephalomyelitis. Indian Pediatr. 2005; 42 (5):479–82.
127. Yucesan C, Arslan O, Arat M, Yucemen N, Ayyildiz E, Ilhan O, et al. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: reviewOf 50 cases. Transfus Apher Sci. 2007; 36 (1):103–7.
128. Ryan LJ, Bowman R, Zantek ND, Sherr G, Maxwell R, Clark HB, et al. Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature. Transfusion.2007; 47(6):981–6.
129. Llufriu S, Castillo J, Blanco Y, Ramio-Torrenta L, Rio J, Valles M, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of im- 274 Neuroimmunology (R Lisak, Section Editor) provement at 6 months. Neurology. 2009; 73 (12):949–53.
130. Yucesan C, Arslan O, Arat M, Yucemen N, Ayyildiz E, Ilhan O, et al. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: reviewOf 50 cases. Transfus Apher Sci. 2007; 36 (1):103–7.
131. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology.2002; 58(1):143–6.
132. RamachandranNair R, Parameswaran M, Girija AS. ADEM treated with plasmapheresis. Singapore Med J. 2005, 46 (10):561–3.
133. Dombrowski KE, Mehta AI, Turner DA, McDonagh DL. Life-saving hemicraniectomy for fulminant ADEM. Br J Neurosurg. 2011; 25 (2):249–52.1
134. Ahmed AI, Eynon CA, Kinton L, Nicoll JAR, Belli A. Decompressive craniectomy for acute disseminated encephalomyelitis. Neurocritical Care.2010; 13(3):393–5.
135. Sekula Jr RF, Marchan EM, Baghai P, Jannetta PJ, Quigley MR. Central brain herniation secondary to fulminant ADEM: implications for neurosurgical management. Case report. Journal of Neurosurgery. 2006; 105 (3):472–4.
136. von Stuckrad-Barre S, Klippel E, Foerch C, Lang JM, du Mesnil de RR, Sitzer M. Hemicraniectomy as a successful treatment of mass effect in acute disseminatedEncephalomyelitis. Neurology.2003; 61(3):420–1.
137. Takata T, Hirakawa M, Sakurai M, Kanazawa I. Fulminant form of acute disseminated encephalomyelitis: successful treatmentwith hypothermia. Journal Of The Neurological Sciences. 1999;165(1):94–7.
138. Leake JA, Billman GF, Nespeca MP, Duthie SE, Dory CE, Meltzer HS, et al. Pediatric acute hemorrhagic leukoencephalitis: report of a surviving patient and review. Clin Infect Dis. 2002; 34(5):699–703.
139. Payne ET, Rutka JT, Ho TK, Halliday WC, Banwell BL. Treatment leading to dramatic recovery in acute hemorrhagic leukoencephalitis. J Child Neurol. 2007, 22 (1):109–13.
140. Ham HY, Lee JK, Jang JW, Seo BR, Kim JH, Choi JW. Post-traumatic cerebral infarction: outcome after decompressive hemicraniectomy for the treatment oftraumatic brain injury. J Korean Neurosurg Soc. 2011; 50 (4):370–6.
141. Panicker JN, Nagaraja D, Kovoor JM, Subbakrishna DK. Descriptive study of acute disseminated encephalomyelitis and evaluation of functional outcome predictors. J Postgrad Med. 2010; 56(1):12–6.
142. Parrish JB, Weinstock-Guttman B, Yeh EA. Cerebellar mutism in pediatric acute disseminated encephalomyelitis. Pediatr Neurol. 2010;42(4):259–66.
143. Mikaeloff Y, Suissa S, Vallee L, Lubetzki C, Ponsot G, Confavreux C, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr. 2004;144(2):246–52.
144. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch- Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56(10):1313–8.

145. de Seze J, Debouverie M, Zephir H, Lebrun C, Blanc F, Bourg V, et al. Acute fulminant demyelinating disease: a descriptive study of 60 patients. ArchNeurol 2007 Oct; 64(10):1426–32.
146. Axer H, Ragoschke-Schumm A, Bottcher J, Fitzek C, Witte OW, Isenmann S. Initial DWI and ADC imaging may predict outcome in acute disseminated encephalomyelitis: report of two cases of brain stem encephalitis. JNeurolNeurosurg Psychiatry. 2005;76(7):996–8.
147. Makhani N, Gorman MP, Branson HM, Stazzone L, Banwell BL, Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology. 2009;72 (24):2076–82.
148. McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A. Immunomodulatory therapies in neurologic critical care. Neurocritical Care. 2010;12(1):132–43.
149. Greenberg BM, Thomas KP, Krishnan C, Kaplin AI, Calabresi PA, Kerr DA. Idipathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology. 2007;68(19):1614–7.
150. Acute Disseminated Encephalomyelitis: Current Understanding and Controversies Nathan P. Young, D.O.,1 Brian G. Weinshenker, M.D.,1 and Claudia F. Lucchinetti, M.D.1
151. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58(1):143–146
152. Marchioni E, Marinou-Aktipi K, Uggetti C, et al. Effectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol 2002;249(1):100– 104
153. Sahlas DJ, Miller SP, Guerin M, Veilleux M, Francis G. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 2000;54(6):1370– 1372
154. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002;59(8):1224–1231
155. Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 2001;56(10): 1313–1318
156. Murthy SN, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002; 110(2 Pt 1): e21
157. Mikaeloff Y, Adams Baum C, Husson B, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004;127(Pt 9):1942–1947 Idrissova ZhR, Boldyreva MN, Dekonenko EP, et al. Acute disseminated encephalomyelitis in children: clinical features and HLA-DR linkage. Eur J Neurol 2003;10(5):537–546
158.158.